Showing results (481-490 of 3,353) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|May 3, 2025
Incidence and prevalence of antimicrobial resistance in outpatients with cancer: a multicentre, retrospective, cohort studyVikas Gupta, Michael J Satlin, Kalvin C Yu, et al.
The Lancet. Oncology|May 3, 2025
Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trialSherko Kuemmel, Monika Graeser, Peter Schmid, et al.
The Lancet. Oncology|May 3, 2025
International consensus on laryngeal preservation strategies in laryngeal and hypopharyngeal cancerMarco Ferrari, Francesca Mularoni, Davide Smussi, et al.
The Lancet. Oncology|October 30, 2025
Artificial Intelligence for Response Assessment in Pediatric Neuro-Oncology (AI-RAPNO), part 1: review of the current state of the artBenjamin H Kann, Arastoo Vossough, Sarah C Brüningk, et al.
The Lancet. Oncology|October 30, 2025
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trialThorsten Fuereder, Javier Garde-Noguera, Juan José García-Mosquera, et al.
The Lancet. Oncology|November 1, 2025
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trialTimothy F Cloughesy, Martin J van den Bent, Mehdi Touat, et al.
The Lancet. Oncology|October 30, 2025
Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trialMatthew Smith, Josep Piulats, Tilman Todenhöfer, et al.
The Lancet. Oncology|October 30, 2025
Physical examinations and whole-body imaging versus physical examinations alone during follow-up after radical surgery of stage IIB-C and III cutaneous malignant melanoma (TRIM): an interim analysis of a multicentre, randomised, phase 3 trial in SwedenCecilia O Ladjevardi, Ylva Naeser, Ulf Dyrke, et al.
The Lancet. Oncology|September 11, 2025
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b studyKelly G Paulson, Sally C M Lau, Myung-Ju Ahn, et al.
The Lancet. Oncology|September 13, 2025
Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trialQuisette P Janssen, Jacob L van Dam, Marlies L van Bekkum, et al.
Pageof 336